I submitted a comment to PubPeer, though it still needs to be approved before showing up. I can still update in case anyone sees any glaring issues.
From the results section of Miana et al.:
According to interviewer instructions for the International Physical Activity Questionnaire (IPAQ)...
If that is the case, they worded it wrong in the text by saying number of days. Still would mean they are walking less anyway.
---
A paper talking about the sitting question being unclear:
What do IPAQ questions mean to older adults? Lessons from cognitive interviews (2010, International...
I thought that doesn't make sense, since 1% of the world population is around 82 million.
Then I found that this figure has other known issues already. It's apparently based on MS, not ME/CFS. The cited paper is: Systematic review and meta-analysis of the prevalence of chronic fatigue...
Note that the above Trial by Error post was also posted in another thread since it pertains to multiple papers: https://www.s4me.info/threads/enduring-symptoms-a-call-to-immediate-action-2025-barnes.47814/post-664382
I think you're right. The questions of the International Physical Activity Questionnaire (IPAQ) related to walking look like what you suggest:
So they walked an average of 27.5 minutes on active days and an average 1.8 active days a week before, and they walked 63.75 min on active days, and...
Long COVID Prevalence and Risk Factors: A Systematic Review and Meta-Analysis of Prospective Cohort Studies
[Line breaks added]
Background: Long COVID, or post-acute sequelae of SARS-CoV-2 infection (PASC), affects millions globally, with persistent symptoms impacting quality of life. This...
Clinical Improvements Following a Non-Aerobic Therapeutic Exercise in Women with Long COVID
[Line breaks added]
Background/Objectives: Long COVID (LC) is characterized by persistent symptoms such as fatigue, pain, and reduced quality of life, often lasting months after acute infection...
Impact of Prior History of Traumatic Stress on Autonomic and Multi-System Symptoms Following COVID-19 Infection
[Line breaks added]
Background
Persistent symptoms of autonomic dysregulation are common after COVID-19 infection and may result from alterations in central and/or peripheral...
I previously wrote this about the supplementary table:
I just came across a 2020 article that explains it:
The Verge: 'Scientists rename human genes to stop Microsoft Excel from misreading them as dates'
Sure enough, the two lines in the table that have a date instead of a gene are "1-Mar"...
That link is for the new double blinded trial, while the updates being discussed are on the pilot study protocol: https://euclinicaltrials.eu/ctis-public/view/2024-512500-19-00?lang=en
Look for anywhere it says "1.7" for the latest updates. There's discussion about clinical response on page 35...
One thing I'm not sure about is whether testing for the newly added 108 participants was done totally separately from the original 37 from the last study.
They say everyone from that last study was ill for up to 179 days ago at the time of testing:
So they would all be in the <200 group, and...
After seeing the data and seeing that these metrics seemed to be worse in people who had been ill longer, they decided to split into two groups to see what the difference between the two groups might be.
They chose 200 days because it splits them cleanly into two groups by their calculated...
Hmm, that's confusing. The paper points to Supplementary Table 7:
But the table doesn't include any of these three that they say are most significant:
Colorectal cancer is most significant, as suggested by the plot above. So I think they looked at the top three terms in their plot above...
PDK4 and PDHA1 were upregulated in the tissues exposed to ME/CFS serum in this study:
They were also upregulated in another study:
Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome, 2016, Fluge et al
Though PDK4 was...
Main points:
The recently posted study is just meant to determine the best dose for a future larger efficacy trial.
It's not yet recruiting or funded. Posting the protocol was the first step in the process to get funding.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.